RxDoctor Payments Data

Steven Prophet, MD

Internal Medicine · Camp Hill, PANPI 1457349102

Payments from drug & device makers

$541in general payments, 2019–2025

Across 25 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$120
  • Astellas Pharma US Inc$99
  • Lilly USA, LLC$65
  • Novartis$51
  • Takeda Pharmaceuticals U.S.A., Inc.$37
  • GSK$32
  • plus $137 from 6 others

What the payments were for

  • Food & beverage$44282%
  • Education$9918%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$541 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$221,883
Medicare patients
569
Services billed
15,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$127,368
JanuviaSitagliptin Phosphate64$70,464
OzempicSemaglutide58$67,039
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$56,342
XareltoRivaroxaban45$46,611
JardianceEmpagliflozin27$35,572
EntrestoSacubitril/Valsartan17$21,130
MyrbetriqMirabegron15$13,077
Repatha SureclickEvolocumab12$11,498
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$10,062
ArexvyRsvpref3 Antigen/As01e/Pf28$8,678
TradjentaLinagliptin12$8,594
Atorvastatin Calcium492$8,411
Combivent RespimatIpratropium/Albuterol Sulfate12$6,591
Breo ElliptaFluticasone/Vilanterol14$6,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$127,368131 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$32$74,92693 claims
MerckJanuvia$26$70,46464 claims
Novo NordiskOzempic$120$67,03958 claims
NovartisEntresto$51$21,13017 claims
Astellas Pharma US IncMyrbetriq$99$13,07715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →